Telix Pharmaceuticals Ltd(TLX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Telix Pharmaceuticals Ltd (TLX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TLX at 36.9/100 on a 32-signal composite quality model, placing it at rank #2,248 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Telix Pharmaceuticals Ltd reports quarterly revenue of $803.8M, net income of $-7.1M. Top institutional holders of TLX by reported 13-F value include FMR, LAZARD ASSET MANAGEMENT, PORTLAND INVESTMENT COUNSEL, based on the most recent SEC filings. TLX trades on the Nasdaq exchange and files with the SEC under CIK 2007191. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Telix Pharmaceuticals Ltd directly from SEC EDGAR.